Drag a card by its title · ⚙ to size, swap or remove

The company

Adaptive Biotechnologies Corporation

ADPT · Nasdaq

Health CareDiagnostics & LabsLeading

ADPT stood above a rising 150-day average in 37 of the last 52 weekly readings, including each of the last 18 weeks. It is 25.2% above that average now. Diagnostics & Labs: 52% of its 44 stocks in an uptrend (+5 points in four weeks); Health Care: 28% (−6 points in four weeks).

SEC filings

Statistics

Rotation: Leading
Weeks in an uptrend: 18 in a row
Industry in uptrend: 52% +5 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $228.7M
Officials’ trades on record: 0
Institutions holding: 282 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 37 of 52 weeks.

22 Apr – 21 Oct

Diagnostics & Labs: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months126

Buyers · sellers0 · 11

Who	Did	Shares	Traded
Julie RubinsteinPresident and COO	sold	5,999at $25.25	21 Oct 2026filed 21 Oct 2026
Julie RubinsteinPresident and COO	sold	5,882at $25.57	21 Oct 2026filed 21 Oct 2026
Julie RubinsteinPresident and COO	sold	11,781at $24.53	20 Oct 2026filed 21 Oct 2026
Julie RubinsteinPresident and COO	sold	100at $24.85	20 Oct 2026filed 21 Oct 2026
Julie RubinsteinPresident and COO	sold	11,881at $24.05	19 Oct 2026filed 21 Oct 2026
Julie RubinsteinPresident and COO	sold	11,581at $24.21	16 Oct 2026filed 16 Oct 2026
Julie RubinsteinPresident and COO	sold	300at $25.45	16 Oct 2026filed 16 Oct 2026
Julie RubinsteinPresident and COO	sold	11,881at $25.61	15 Oct 2026filed 16 Oct 2026
Julie RubinsteinPresident and COO	sold	6,781at $25.57	14 Oct 2026filed 16 Oct 2026
Julie RubinsteinPresident and COO	sold	5,100at $25.82	14 Oct 2026filed 16 Oct 2026
Julie RubinsteinPresident and COO	sold	11,881at $25.50	13 Oct 2026filed 13 Oct 2026
Julie RubinsteinPresident and COO	sold	9,181at $25.35	12 Oct 2026filed 13 Oct 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders282+2 on the quarter

New · exited49 · 47

Reported value$3.2B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
VIKING GLOBAL INVESTORS LPunchanged · filed 14 Aug 2026	29,993,708$643.4M	00.0%
BlackRock, Inc.added · filed 7 Aug 2026	15,139,159$324.7M	+1,836,134+13.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	6,403,587$137.4M	+309,443+5.1%
WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 2026	5,911,366$126.8M	+2,053,944+53.2%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026	5,476,231$117.5M	+984,757+21.9%
D. E. Shaw & Co., Inc.added · filed 14 Aug 2026	4,625,859$99.2M	+2,660,249+135.3%
WESTFIELD CAPITAL MANAGEMENT CO LPreduced · filed 12 Aug 2026	4,267,645$91.5M	-1,169,073−21.5%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	3,641,837$78.1M	+5,783+0.2%
STATE STREET CORPadded · filed 7 Aug 2026	3,458,388$74.2M	+231,143+7.2%
Invesco Ltd.reduced · filed 14 Aug 2026	3,094,011$66.4M	-1,356,055−30.5%

31 Mar 2023 – 30 Jun 2026

News

Adaptive Biotechnologies Spotlights MRD Testing In Myeloma Cure Criteriarttnews.com · 25 Sep 2026 Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Curemanilatimes.net · 25 Sep 2026 Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?insidermonkey.com · 23 Sep 2026 Biotech Stocks At 52-Week Highs - BlossomHill Therapeutics +18% On Positive Trial Data, Adaptive Biotechnologies, Illumina, CeriBell, Neogenfinanznachrichten.de · 17 Sep 2026

Everyone who traded it

Julie Rubinstein President and COO · last 21 Oct 20260 · 118

Susan Bobulsky Chief Commercial Officer, MRD · last 6 Oct 20260 · 14

Francis Lo Chief People Officer · last 1 Oct 20261 · 32

Katey Einterz Owen Director · last 31 Aug 20260 · 1

Chad M. Robins CEO and Chairman · last 18 Aug 20260 · 86

Robert Hershberg Director · last 18 Aug 20260 · 16

Peter M. Neupert Director · last 17 Aug 20260 · 2

Harlan S. Robins Chief Scientific Officer · last 21 Jul 20260 · 88

Sharon Benzeno Chief Commercial Ofc Imm Med · last 29 Jun 20260 · 35

Michelle Renee Griffin Director · last 25 Jun 20260 · 19

Kyle Piskel Chief Financial Officer · last 18 May 20260 · 16

Michael J. Pellini Director · last 4 Mar 20250 · 4

Same industry

CDNA CareDxLeading+97%

NTRA NateraLeading+51%

XGN ExagenLeading+49%

FTRE Fortrea HoldingsLeading+49%

PSNL PersonalisLeading+35%

GH Guardant HealthLeading+22%

BDSX BiodesixLeading+19%

NEOG NeogenLeading+14%

Distance from each stock’s own 150-day average.

Government contracts

Awards1

Total$39K

Latest28 Sep 2026

ADAPTIVE BIOTECHNOLOGIES CORPORATION:1186779 [26-010014]Department of Health and Human Services · $39K · 28 Sep 2026

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202574.2%

Operating profit marginFY 2025 · to 31 Dec 2025-20.6%

Free cash flow marginFY 2025 · to 31 Dec 2025-17.7%

Return on capital employedFY 2025 · to 31 Dec 2025-13.5%

Debt to equityFY 2025 · to 31 Dec 20250.60×

Interest coverFY 2025 · to 31 Dec 2025-4.85×

Research spendFY 2025 · to 31 Dec 202533.9%

Share count trendFY 2025 · to 20 Feb 20260.1%

Cash and equivalentsFY 2025 · to 31 Dec 2025$70.5M

Free cash flowFY 2025 · to 31 Dec 2025−$48.9M

Analyst forecasts

No analyst forecasts yet.